Buried deep within large datasets are answers to long-standing questions about healthcare in the United States: Why is it so expensive? Why do prices vary so widely across the country?
When Zack Cooper, PhD, arrived at Yale as assistant professor of public health and economics, he gained access to a first-of-its-kind dataset. Working with the non-profit Health Care Cost Institute, Dr Cooper and colleagues at Carnegie Mellon University and the London School of Economics gathered insurance claims data from 3 of the nation’s largest private health insurers.
Buried deep within the large dataset are answers to long-standing questions about healthcare in the United States: Why is it so expensive? Why do prices vary so widely across the country? And what, if anything, can stop costs from rising further? While answers to these questions are still being analyzed, YaleNews spoke to Dr Cooper about his work and its potential impact on the healthcare market.
Read more at YaleNews: http://bit.ly/19qp8Za
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Homelessness Compounds Hospital Stay Challenges: Study Reveals Prolonged Discharge Struggles
March 28th 2024In this investigation, outcomes of interest were morbidity rate and length of hospital stay or a traumatic injury among a homeless population, and whether age and/or injury severity had an influence on that relationship—with implications for improving the discharge process for these patients.
Read More
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More